Rare monosomy 7 and deletion 7p at diagnosis of chronic myeloid leukemia in accelerated phase

Cancer Genet. 2021 Apr:252-253:111-114. doi: 10.1016/j.cancergen.2021.01.006. Epub 2021 Jan 19.

Abstract

Clonal cytogenic evolution with the development of additional chromosomal abnormalities (ACAs) in chronic myelogenous leukemia (CML) is a marker for disease progression and is known to impact therapy and survival. The presence of ACAs has been shown to affect the responses to tyrosine kinase inhibitors (TKI) in patients with newly diagnosed CML in accelerated phase (CML-AP). We report a rare case of a CML patient who presented in CML-AP and was found to have multiple ACAs including monosomy 7, deletion 7p, trisomy 8, and an extra Philadelphia chromosome (Ph) in separate Ph-positive cell line, respectively. Six months after combined chemotherapy with TKI, the patient achieved a major cytogenetic response with disappearance of monosomy 7/deletion 7p with no major molecular response.

Keywords: Additional chromosomal abnormalities; Chronic myelogenous leukemia; Clonal cytogenic evolution; Deletion 7p; Monosomy 7; Philadelphia chromosome.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use
  • Chromosome Deletion*
  • Chromosomes, Human, Pair 7
  • Humans
  • Karyotyping
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Male

Substances

  • Antineoplastic Agents

Supplementary concepts

  • Chromosome 7, monosomy